CN104244978A - 通过施用丝氨酸蛋白酶抑制剂治疗或预防流感病毒感染的方法 - Google Patents

通过施用丝氨酸蛋白酶抑制剂治疗或预防流感病毒感染的方法 Download PDF

Info

Publication number
CN104244978A
CN104244978A CN201380020133.9A CN201380020133A CN104244978A CN 104244978 A CN104244978 A CN 104244978A CN 201380020133 A CN201380020133 A CN 201380020133A CN 104244978 A CN104244978 A CN 104244978A
Authority
CN
China
Prior art keywords
pharmaceutical composition
tmprss2
influenza
ttsp
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380020133.9A
Other languages
English (en)
Chinese (zh)
Inventor
L·A·珀塞尔恩嘉波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN104244978A publication Critical patent/CN104244978A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201380020133.9A 2012-04-16 2013-04-15 通过施用丝氨酸蛋白酶抑制剂治疗或预防流感病毒感染的方法 Pending CN104244978A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261624519P 2012-04-16 2012-04-16
US61/624,519 2012-04-16
US201361759469P 2013-02-01 2013-02-01
US61/759,469 2013-02-01
PCT/US2013/036522 WO2013158516A1 (en) 2012-04-16 2013-04-15 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

Publications (1)

Publication Number Publication Date
CN104244978A true CN104244978A (zh) 2014-12-24

Family

ID=48184523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380020133.9A Pending CN104244978A (zh) 2012-04-16 2013-04-15 通过施用丝氨酸蛋白酶抑制剂治疗或预防流感病毒感染的方法

Country Status (14)

Country Link
US (1) US9498529B2 (https=)
EP (2) EP3536342A1 (https=)
JP (2) JP6446355B2 (https=)
KR (1) KR20150008383A (https=)
CN (1) CN104244978A (https=)
AU (2) AU2013249577A1 (https=)
BR (1) BR112014025339A8 (https=)
CA (2) CA3219083A1 (https=)
HK (1) HK1202817A1 (https=)
MX (1) MX2014012285A (https=)
NZ (1) NZ631105A (https=)
SG (1) SG11201405163RA (https=)
WO (1) WO2013158516A1 (https=)
ZA (1) ZA201406194B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936517A (zh) * 2018-01-26 2020-11-13 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
KR101693243B1 (ko) * 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
MX2022009476A (es) 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195119A1 (en) * 2020-03-24 2021-09-30 Corcept Therapeutics Incorporated Methods of reducing the risk of, severity of, and treating coronavirus infections
EP3964207A1 (en) 2020-09-02 2022-03-09 Christian-Albrechts-Universität zu Kiel Antiviral pharmaceutical composition for topical administration
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308438A (ja) * 2007-06-14 2008-12-25 Mitsubishi Tanabe Pharma Corp 新規なインフルエンザ治療および／または予防薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4839999A (en) * 1998-06-29 2000-01-17 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
JP5366406B2 (ja) * 2005-01-07 2013-12-11 レキシコン ファーマシューティカルズ インコーポレーテッド アンジオポエチン様タンパク質４（ａｎｇｐｔｌ４）に対するモノクローナル抗体
WO2007089903A2 (en) 2006-02-01 2007-08-09 Brigham Young University Cationic steroid microbial compositions for treating or preventing influenza infections
JP2008247864A (ja) * 2007-03-30 2008-10-16 Univ Of Tokushima モザイクセリンプロテアーゼ、ｍｓｐとその用途
BRPI1014745B1 (pt) 2009-06-22 2020-10-20 Borealis Ag artigo para interior de automóveis com odor reduzido
DK3702374T3 (da) * 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308438A (ja) * 2007-06-14 2008-12-25 Mitsubishi Tanabe Pharma Corp 新規なインフルエンザ治療および／または予防薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EVA BO¨TTCHER-FRIEBERTSHA¨USER ET AL.: "Inhibition of Influenza Virus Infection in Human Airway Cell Cultures by an Antisense Peptide-Conjugated Morpholino Oligomer Targeting the Hemagglutinin-Activating Protease TMPRSS2", 《JOURNAL OF VIROLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936517A (zh) * 2018-01-26 2020-11-13 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
CN111936517B (zh) * 2018-01-26 2025-04-18 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段

Also Published As

Publication number Publication date
WO2013158516A1 (en) 2013-10-24
JP2018048169A (ja) 2018-03-29
AU2018200265A1 (en) 2018-02-01
HK1202817A1 (en) 2015-10-09
NZ631105A (en) 2016-09-30
EP3536342A1 (en) 2019-09-11
JP6446355B2 (ja) 2018-12-26
BR112014025339A8 (pt) 2018-01-16
CA3219083A1 (en) 2013-10-24
JP2015516975A (ja) 2015-06-18
ZA201406194B (en) 2016-08-31
US20130273070A1 (en) 2013-10-17
MX2014012285A (es) 2015-04-13
US9498529B2 (en) 2016-11-22
AU2013249577A1 (en) 2014-10-02
AU2018200265B2 (en) 2019-07-18
BR112014025339A2 (pt) 2013-10-24
CA2869010A1 (en) 2013-10-24
KR20150008383A (ko) 2015-01-22
EP2838558A1 (en) 2015-02-25
SG11201405163RA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US11964016B2 (en) Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2018200265B2 (en) Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
US20230102151A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20230203176A1 (en) Methods For Prevention Of Graft Rejection In Xenotransplantation
HK40014386A (en) Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
HK40103467A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
HK40010552A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
HK40010552B (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141224